Search research articles
Contact Us
Filters
Showing results (41-50 of 71) with videos related to
Page
of 8
Sort By:
Inflammatory Bowel Diseases
|
February 22, 2017
The α4β1 Homing Pathway Is Essential for Ileal Homing of Crohn's Disease Effector T Cells In Vivo
Sebastian Zundler, Anika Fischer, Daniela Schillinger, et al.
Gut
|
July 26, 2015
Differential effects of α4β7 and GPR15 on homing of effector and regulatory T cells from patients with UC to the inflamed gut in vivo
Anika Fischer, Sebastian Zundler, Raja Atreya, et al.
BMC Gastroenterology
|
April 16, 2020
Baseline levels of dynamic CD4<sup>+</sup> T cell adhesion to MAdCAM-1 correlate with clinical response to vedolizumab treatment in ulcerative colitis: a cohort study
Clarissa Allner, Michaela Melde, Emily Becker, et al.
Therapeutic Advances in Gastroenterology
|
December 6, 2021
α4β7 integrin-dependent adhesion of T cells to MAdCAM-1 is blocked by vedolizumab in patients with chronic refractory pouchitis
Michaela Melde, Tanja M Müller, Ines Schneider, et al.
Frontiers in Immunology
|
November 11, 2017
Good Manufacturing Practice-Compliant Production and Lot-Release of <i>Ex Vivo</i> Expanded Regulatory T Cells As Basis for Treatment of Patients with Autoimmune and Inflammatory Disorders
Manuel Wiesinger, Diane Stoica, Susanne Roessner, et al.
Translational Research : the Journal of Laboratory and Clinical Medicine
|
October 22, 2022
Expression and function of α4β7 integrin predict the success of vedolizumab treatment in inflammatory bowel disease
Ines Schneider, Clarissa Allner, Laura Mühl, et al.
Frontiers in Pharmacology
|
February 19, 2019
Cellular Mechanisms of Etrolizumab Treatment in Inflammatory Bowel Disease
Charlotte Lichnog, Sha Klabunde, Emily Becker, et al.
The Journal of Investigative Dermatology
|
January 1, 2022
Transcriptomes of MPO-Deficient Patients with Generalized Pustular Psoriasis Reveals Expansion of CD4<sup>+</sup> Cytotoxic T Cells and an Involvement of the Complement System
Stefan Haskamp, Benjamin Frey, Ina Becker, et al.
Clinical and Translational Medicine
|
April 8, 2023
Anti-β7 integrin treatment impedes the recruitment on non-classical monocytes to the gut and delays macrophage-mediated intestinal wound healing
Katrin Sommer, Karin Heidbreder, Lucas Kreiss, et al.
Gut
|
August 31, 2021
Residual homing of α4β7-expressing β1<sup>+</sup>PI16<sup>+</sup> regulatory T cells with potent suppressive activity correlates with exposure-efficacy of vedolizumab
Emily Becker, Mark Dedden, Christine Gall, et al.
Page
of 8
Search research articles
Search
Showing results (41-50 of 71) with videos related to
Sort By:
Page
of 8
Inflammatory Bowel Diseases
|
February 22, 2017
The α4β1 Homing Pathway Is Essential for Ileal Homing of Crohn's Disease Effector T Cells In Vivo
Sebastian Zundler, Anika Fischer, Daniela Schillinger, et al.
Gut
|
July 26, 2015
Differential effects of α4β7 and GPR15 on homing of effector and regulatory T cells from patients with UC to the inflamed gut in vivo
Anika Fischer, Sebastian Zundler, Raja Atreya, et al.
BMC Gastroenterology
|
April 16, 2020
Baseline levels of dynamic CD4<sup>+</sup> T cell adhesion to MAdCAM-1 correlate with clinical response to vedolizumab treatment in ulcerative colitis: a cohort study
Clarissa Allner, Michaela Melde, Emily Becker, et al.
Therapeutic Advances in Gastroenterology
|
December 6, 2021
α4β7 integrin-dependent adhesion of T cells to MAdCAM-1 is blocked by vedolizumab in patients with chronic refractory pouchitis
Michaela Melde, Tanja M Müller, Ines Schneider, et al.
Frontiers in Immunology
|
November 11, 2017
Good Manufacturing Practice-Compliant Production and Lot-Release of <i>Ex Vivo</i> Expanded Regulatory T Cells As Basis for Treatment of Patients with Autoimmune and Inflammatory Disorders
Manuel Wiesinger, Diane Stoica, Susanne Roessner, et al.
Translational Research : the Journal of Laboratory and Clinical Medicine
|
October 22, 2022
Expression and function of α4β7 integrin predict the success of vedolizumab treatment in inflammatory bowel disease
Ines Schneider, Clarissa Allner, Laura Mühl, et al.
Frontiers in Pharmacology
|
February 19, 2019
Cellular Mechanisms of Etrolizumab Treatment in Inflammatory Bowel Disease
Charlotte Lichnog, Sha Klabunde, Emily Becker, et al.
The Journal of Investigative Dermatology
|
January 1, 2022
Transcriptomes of MPO-Deficient Patients with Generalized Pustular Psoriasis Reveals Expansion of CD4<sup>+</sup> Cytotoxic T Cells and an Involvement of the Complement System
Stefan Haskamp, Benjamin Frey, Ina Becker, et al.
Clinical and Translational Medicine
|
April 8, 2023
Anti-β7 integrin treatment impedes the recruitment on non-classical monocytes to the gut and delays macrophage-mediated intestinal wound healing
Katrin Sommer, Karin Heidbreder, Lucas Kreiss, et al.
Gut
|
August 31, 2021
Residual homing of α4β7-expressing β1<sup>+</sup>PI16<sup>+</sup> regulatory T cells with potent suppressive activity correlates with exposure-efficacy of vedolizumab
Emily Becker, Mark Dedden, Christine Gall, et al.
Page
of 8